Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SLC26A6 | Q9BXS9 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | BMP1 | P13497 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8825216 | 0.81 | CYP1A2 (0.43) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4489619 | 0.79 | KMT2A (0.40) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| Hydrochloric Acid SCHEMBL6328451 | 0.78 | KMT2A (0.40) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| Hydrochloric Acid SCHEMBL4489615 | 0.78 | KMT2A (0.40) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL11143466 | 0.78 | NPC1 (0.38) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL11143469 | 0.78 | NPC1 (0.38) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6323045 | 0.77 | MMP2 (0.39) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL13163078 | 0.77 | MMP2 (0.48) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL1934380 | 0.77 | SLC26A6 (0.40) | ALDH1A1SLC26A6MMP2BMP1KMT2A | |
| SCHEMBL31157814 | 0.77 | MMP2 (0.38) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994142-A | Furanamide compound and application thereof | 浙江大学金华研究院 | 2024-11-22 | — | — | CN | disclosed |
| EP-3097101-B1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10065945-B2 | Isoquinoline derivatives as MGAT2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180009796-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-01-11 | — | — | US | disclosed |
| EP-3097101-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112465-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2010052199-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009796-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MGAT2, MGAT1, ACAT2 | ALDH1A1 663/4885CACNA1F 1613/4885CACNA1D 2094/4885 |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | BACE1, APH1A, APP | ALDH1A1 3285/4885CACNA1F 307/4885CACNA1D 241/4885 |
| US-10065945-B2 | Isoquinoline derivatives as MGAT2 inhibitors | MGAT2, MGAT1, ACAT2 | ALDH1A1 663/4885CACNA1F 1613/4885CACNA1D 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.